2005•PubMedRequires access

[Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits].

Zhaohui Wang, Feng Roger Luo, Xiaomei Liu

Open publisher page 8 citations

Abstract

AIM: To explore the prevention of atherosclerosis by PPARy agonist rosiglitazone. METHODS: 24 male New Zealand white rabbits weighing 1.8 to 2.2 kg were randomly divided into 3 groups: control group, normal rabbit chow; cholesterol group, 1% cholesterol diet; rosiglitazone group, 1% cholesterol diet supplemented with rosiglitazone 0.5 mg x kg(-1) x d(-1) for 6 weeks. Rabbits in cholesterol group and rosiglitazone group were sequentially fed 1% cholesterol-containing diet for 16 weeks. At the end of the experiment, blood glucose, serum lipids levels, ratio of plaque area to aorta area and ratio of intima to media were determined. RESULTS: Hypercholesterolemia was successfully reproduced in rabbits. Adnimistration of rosiglitazone significantly decreased serum TC and LDL-C. The ratio of intima to media and ratio of plaque area to aorta area were also reduced. CONCLUSION: Rosiglitazone could prevent atherosclerosis by decreasing levels of TC and LDL-C.

About this research paper

What this paper is about

AIM: To explore the prevention of atherosclerosis by PPARy agonist rosiglitazone. METHODS: 24 male New Zealand white rabbits weighing 1.8 to 2.2 kg were randomly divided into 3 groups: control group, normal rabbit chow; cholesterol group, 1% cholesterol diet; rosiglitazone group, 1% cholesterol diet supplemented with rosiglitazone 0.5 mg x kg(-1) x d(-1) for 6 weeks. Rabbits in cholesterol group and rosiglitazone group were sequentially fed 1% cholesterol-containing diet for 16 weeks. At the end of the experiment, blood glucose, serum lipids levels, ratio of plaque area to aorta area and ratio of intima to media were determined. RESULTS: Hypercholesterolemia was successfully reproduced in rabbits. Adnimistration of rosiglitazone significantly decreased serum TC and LDL-C. The ratio of intima to media and ratio of plaque area to aorta area were also reduced. CONCLUSION: Rosiglitazone could prevent atherosclerosis by decreasing levels of TC and LDL-C.

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM: To explore the prevention of atherosclerosis by PPARy agonist rosiglitazone. METHODS: 24 male New Zealand white rabbits weighing 1.8 to 2.2 kg were randomly divided into 3 groups: control group, normal rabbit chow; cholesterol group, 1% cholesterol diet; rosiglitazone group, 1% cholesterol diet supplemented with rosiglitazone 0.5 mg x kg(-1) x d(-1) for 6 weeks. Rabbits in cholesterol group and rosiglitazone group were sequentially fed 1% cholesterol-containing diet for 16 weeks. At the end of the experiment, blood glucose, serum lipids levels, ratio of plaque area to aorta area and ratio of intima to media were determined. RESULTS: Hypercholesterolemia was successfully reproduced in rabbits. Adnimistration of rosiglitazone significantly decreased serum TC and LDL-C. The ratio of intima to media and ratio of plaque area to aorta area were also reduced. CONCLUSION: Rosiglitazone could prevent atherosclerosis by decreasing levels of TC and LDL-C.

Key concepts: Rosiglitazone, Internal medicine, Endocrinology, Cholesterol, Agonist, Aorta, Medicine, Blood lipids

Related papers

Back to paper searchBrowse research topicsOriginal source
[Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits]. — Research Paper | ScholarLens